Indian Immunologicals Launches Classical Swine Fever Vaccine ‘Raksha Class’ for Pigs in India
- It can prevent high mortality and help increase pig population in India
- Indian Pig Growers suffer Rs 400 Crore Losses due to the Classical Swine Fever
Hyderabad, 28th May 2020: Indian Immunologicals Limited (IIL), a leading veterinary and human vaccines manufacturing company, today announced the launch of the Classical Swine Fever (CSF) vaccine under the brand 
name – ‘Raksha Class’- into the market. This unique cell culture technology-based vaccine has been developed in collaboration with the Indian Veterinary Research Institute (IVRI), Bareilly.
The Classical Swine Fever (CSF) is a highly contagious viral disease of pigs caused by an RNA virus. This disease has a high fatality rate and therefore, pig growers face serious economic problems with the loss of the herd. The Raksha Class vaccine is a live attenuated vaccine and has been tested for safety, sterility, and potency. The field trials for the vaccine were conducted at Bengaluru and Hyderabad Veterinary colleges. Raksha Class offers distinct advantages in terms of safety and can be scaled up in cell cultures to meet entire country’s requirements. The current requirement is about 22 million doses and the supply is less than a million doses.
The current vaccines manufactured by a few state biologicals depend on the rabbits for vaccine production, where consistency in yields, virus titres, safety and efficacy might not be achieved to the desired levels. IIL’s manufacturing facilities can make several million doses of the vaccine.
Speaking on the occasion, Dr K Anand Kumar, Managing Director, Indian Immunologicals Limited said, “The Classical Swine Fever is one of the major diseases of pigs in India. It causes a loss of about Rs. 400 crores per annum in India. The disease has led to a decrease of pig population in the country. With the launch of Raksha Class, we can ensure that the pig population in India can be increased and hence, the growers will be immensely benefited economically”.
Elaborating the pig farming in the country, Dr Prasanna Deshpande, Dy. Managing Director, Indian Immunologicals Limited said, “The current pig population in India is estimated to be around 9 million. More than 50% of these piggery units are concentrated in North east region of the country. Classical Swine Fever is prevalent in almost all the states where this pig population exists. Raksha Class will address the country’s requirements and offer the vaccine at an affordable cost to the growers in India”.
Indian Immunologicals Limited was also the first company in the world to launch a vaccine for porcine cysticercosis – Cysvax – which targets a major parasitic disease that causes approximately 40% of epilepsy in humans in the developing world.
It is recalled that Indian Immunologicals Limited is leading the research to develop a Live Attenuated COVID-19 vaccine based on codon de-optimization technology in collaboration with Griffith University of Australia.
About Indian Immunologicals Limited:
Indian Immunologicals Limited headquartered in Hyderabad, India is the market leader in veterinary biologicals and the third largest animal health and human health player in India. IIL was set up by the National Dairy Development Board (NDDB) in 1982 and pursues a one health approach to improve and extend lives. IIL is one of the largest producers of Foot and Mouth disease vaccine in the world and was the first company in India to launch the purified Vero cell rabies vaccine for humans (PVRV) and second globally. IIL has strong R&D and has launched several animal and human vaccines in the Indian market at affordable prices. R&D at IIL, specializes in the development of varied types of vaccines ranging from inactivated and live viral vaccines, polysaccharide conjugate vaccines, recombinant subunit vaccines, toxoid vaccines, bacterial vaccines, and molecular vaccines. More details about the company can be viewed on www.indimmune.com.
No comments:
Post a Comment